Quarterly report pursuant to Section 13 or 15(d)

Business and Liquidity (Details)

v2.4.0.6
Business and Liquidity (Details) (USD $)
3 Months Ended 9 Months Ended 1 Months Ended 0 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
item
Sep. 30, 2011
Dec. 31, 2011
Feb. 22, 2011
Convertible Notes
Jul. 02, 2012
Convertible Notes
Second Tranche
Business and Liquidity              
Period since the entity has begun commercialization outside the United States of its newest product, RenalGuard     4 years        
Number of operating segments     1        
Loss from continuing operations $ (1,095,000) $ (893,000) $ (3,230,000) $ (2,442,000)      
Cash used in operations     2,564,000 2,972,000      
Accumulated deficit 110,115,000   110,115,000   98,727,000    
Number of independent investigator-sponsored clinical trials     2        
Additional capital raised              
Additional capital raised through the completion of additional financing by the closing on the second tranche of convertible notes           $ 4,000,000 $ 1,000,000